9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

A.Inoue; K.Kobayashi; M.Maemondo; S.Sugawara; S.Oizumi; Y.Saijo; A.Genma; S.Morita; K.Hagiwara; T.Nukiwa

首页> 外文期刊>European Journal of Cancer Supplements >9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

【24h】

9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

机译：9LBA一项将吉非替尼与卡铂（CBDCA）加紫杉醇（TXL）用于具有敏感EGFR突变的非小细胞肺癌（NSCLC）一线治疗的随机III期研究：NEJ002研究

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第3期|共1页
作者
A.Inoue; K.Kobayashi; M.Maemondo; S.Sugawara; S.Oizumi; Y.Saijo; A.Genma; S.Morita; K.Hagiwara; T.Nukiwa;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study [J] . A.Inoue, K.Kobayashi, M.Maemondo, European Journal of Cancer Supplements . 2009,第3期

机译：9LBA一项将吉非替尼与卡铂（CBDCA）加紫杉醇（TXL）用于具有敏感EGFR突变的非小细胞肺癌（NSCLC）一线治疗的随机III期研究：NEJ002研究
2. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002) [J] . Miyauchi Eisaku, Inoue Akira, Kobayashi Kunihiko, Japanese journal of clinical oncology. . 2015,第7期

机译：吉非替尼一线治疗后EGFR突变阳性的晚期非小细胞肺癌的化疗效果-来自吉非替尼与卡铂加紫杉醇（NEJ002）比较的随机III期研究数据
3. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na?ve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J] . Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第1期

机译：最新的总体生存结果来自一项随机的，比较吉非替尼与卡铂-紫杉醇治疗具有敏感性EGFR基因突变的非小细胞肺癌的三期临床试验（NEJ002）
4. In Non-Small Cell Lung Cancer, Can Radiomic Features Predict EGFR Mutations? [C] . Jiayan Liu, Lin Liu, Yue Ma, IEEE International Conference on Mechatronics and Automation . 2019

机译：在非小细胞肺癌中，放射学特征可以预测EGFR突变吗？
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR [O] . Yoon Ji Choi, Dae Ho Lee, Chang Min Choi, 2015

机译：在临床选择的人群中除非吸烟腺癌或EGFR突变患者外对于未经化疗的初次非小细胞肺癌与单独使用紫杉醇/卡铂比较的紫杉醇/卡铂联合吉非替尼的随机II期研究
7. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR [O] . Yoon Ji Choi, Dae Ho Lee, Chang Min Choi, 2015

机译：在临床选择的人群中，不包括非吸烟腺癌或EGFR突变患者的未经化疗的非小细胞肺癌随机对照II期紫杉醇/卡铂联合吉非替尼与紫杉醇/卡铂比较

9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

著录项

引文网络

相似文献

相关主题

期刊订阅